FDA reviewing sBLA for Pegintron for melanoma

Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma.

KENILWORTH, New JerseySchering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. The agent is currently approved for use in the treatment of chronic hepatitis C. The company said that FDA's Oncology Drugs Advisory Committee will discuss the application at its meeting in March.

Articles in this issue

almost 19 years ago

Article

NLST article not balanced, critic of screening trial asserts

almost 19 years ago

Article

M.D. Anderson and AstraZeneca form neuropathic pain alliance

almost 19 years ago

Article

Good nilotinib responses in imatinib-resistant AP-CML

almost 19 years ago

Article

Virus linked to Merkel cell carcinoma

almost 19 years ago

Article

Benefit of adjuvant RT/CT for pancreatic ca affirmed

almost 19 years ago

Article

Recurrence Score helps select node+ pts for chemo

almost 19 years ago

Article

For resectable liver mets: Preop chemotherapy or not?

almost 19 years ago

Article

Plerixafor boosts stem cell mobilization in myeloma pts

almost 19 years ago

Article

MRI shows second-hand smoke damage

almost 19 years ago

Article

Assay has high sensitivity for hard-to-detect SLN mets

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

October 31st, 2026

Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma

Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.